|
|
Official Name
|
English
|
|
Allogeneic Multi-Virus Specific T Lymphocytes Targeting Respiratory Syncytial Virus (RSV), Influenza, Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV)
|
|
|
Common Name
|
English
|
|
ALVR106 is a polyclonal (CD4+ and CD8+) virus-specific T cell product containing cells that are reactive against four viruses (RSV, Influenza, PIV, and hMPV). The cells are derived from peripheral blood mononuclear cells (PBMCs) from donors seropositive
|
|
|
Common Name
|
English
|
|
|
Code
|
English
|
|
ALVR106 is comprised of both CD8+ and CD4+ virus-specific T cells capable of recognizing actively replicating virus-infected cells, proliferating in response to antigenic stimulation and mediating antiviral effects including the production of cytokines a
|
|
|
Common Name
|
English
|
|
ALVR106 is a novel virus-specific cell-based therapy to treat four respiratory viral infections that are a serious cause of morbidity and mortality in immunocompromised patients. ALVR106 is under development to treat four respiratory viral infections (re
|
|
|
Common Name
|
English
|
|
|
Common Name
|
English
|
|
|
Code
|
English
|
